10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The company's integrated solutions include instruments, consumables, and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. Its product offerings include a Chromium platform comprising microfluidic chips and related consumables, Chromium X series, Visium and Xenium platforms, and others, which are predominantly used for the study of biological components. Geographically, the company derives operates from the United States and the rest from Americas (excluding the United States), Europe, Middle East and Africa, China, and Asia-Pacific (excluding China).
Last trade$56.41
Day change+$1.42 (+2.58%)
Day range$52.73 – $57.62
Volume1,881,415
Market cap$7.23B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$7.23B
Price / earnings
—
Price / book
8.63×
Price / sales
11.69×
EV / sales
10.84×
EV / EBITDA
-184.21×
Profitability
Earnings per share
-$0.51
Return on assets
-6.31%
Return on equity
-8%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
5.12×
Quick ratio
4.66×
Cash ratio
3.75×
Cash flow
Price / cash flow
72.55×
Price / free cash flow
74.55×
Free cash flow
$97.02M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for TXG, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$150.67M
$151.04M
$150.84M
$166.03M
$149M
$172.91M
$154.88M
$165.02M
Cost of revenue
$37.74M
$38.54M
$44.67M
$52.99M
$48.7M
$47.82M
$49.44M
$54.07M
Gross profit
$112.93M
$112.5M
$106.18M
$113.05M
$100.31M
$125.08M
$105.45M
$110.96M
Selling, general and administrative
$76.06M
$78.66M
$66.38M
$76.62M
$75.36M
$74.43M
$89.73M
$93.83M
Research and development
$52.93M
$56.79M
$56.85M
$55.97M
$57.19M
$61.22M
$64.25M
$66.97M
Total operating expenses
$128.98M
$132.05M
$123.22M
$132.59M
$132.55M
$94.96M
$144.77M
$160.79M
Operating income
-$16.06M
-$19.56M
-$17.05M
-$19.54M
-$32.24M
$30.13M
-$39.33M
-$49.84M
Interest expense
$0
$0
$0
$0
$3K
-$3K
$0
$0
Income before taxes
-$18.48M
-$18.65M
-$12.85M
-$15.19M
-$28.21M
$37M
-$33.51M
-$48.38M
Income taxes
$949K
-$714K
$623K
$1.06M
-$733K
$2.46M
$852K
$648K
Net income
-$19.43M
-$17.93M
-$13.47M
-$16.25M
-$27.47M
$34.54M
-$34.36M
-$49.03M
Net income attributable to common shareholders
-$19.43M
-$17.93M
-$13.47M
-$16.25M
-$27.47M
$34.54M
-$34.36M
-$49.03M
EBITDA
-$6.55M
-$13.29M
-$7.09M
-$9.48M
-$21.95M
-$2.76M
-$40.51M
-$41.09M
Basic earnings per share
-$0.15
-$0.14
-$0.10
-$0.13
-$0.22
$0.28
-$0.28
-$0.40
Diluted earnings per share
-$0.15
-$0.14
-$0.10
-$0.13
-$0.22
$0.28
-$0.28
-$0.40
Recent news
Company coverage with links to the original publishers.
10x Genomics announced that Fudan University Shanghai Cancer Center and Shanghai Precision Diagnostics will use its Xenium platform in a 24-month breast cancer biomarker study analyzing tumor biopsies from 500 patients. The collaboration aims to identify biomarkers predicting treatment response to neoadjuvant therapy, potentially advancing personalized cancer diagnostics. TXG stock has surged 264.7% year-to-date, outperforming broader markets.
10x Genomics raised its 2026 revenue guidance to $625-$635M from $610-$630M, driven by strong early demand for its Atera spatial biology platform and resilient consumables sales. The company expects approximately 50 Atera shipments by year-end, up from 40, but faces manufacturing and installation capacity constraints. Q4 gross margins are expected to decline to the low-to-mid-60% range due to increased Atera shipments, with margin pressure continuing into 2027.
10x Genomics reported Q3 2026 revenue of $150.67 million, up 1.1% year-over-year and beating consensus estimates by 2.35%. The company posted an EPS of -$0.15, significantly outperforming the estimated -$0.29 with a 48.28% surprise. Consumables revenue grew 5% and Spatial segment showed strong growth at 16.4%, but Instruments revenue declined 42.9% year-over-year. The stock has underperformed the broader market, down 11.3% over the past month.
The global genomics market is projected to reach $99.26 billion by 2034, growing at 12.66% CAGR. Three stocks—Illumina, uniQure, and 10x Genomics—are highlighted as potential investments in this expanding sector, all carrying Zacks Rank #2 (Buy) ratings. Recent advances in DNA sequencing, gene therapies, and genome-editing technologies like CRISPR are driving growth in personalized medicine and synthetic biology applications.
Butterfly Network reported a Q3 loss of $0.01 per share, beating consensus estimates of $0.03 loss, with a 66.67% earnings surprise. Revenue reached $32.6 million, surpassing estimates by 16.05% and up 51.7% year-over-year. The stock has gained 105.5% year-to-date but holds a Zacks Rank #3 (Hold) rating with mixed estimate revisions.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.